Inhibition of tumor angiogenesis by targeting Endothelial surface ATP synthase with sangivamycin

Yusuke Komi, Osamu Ohno, Yasuhiro Suzuki, Mariko Shimamura, Kentaro Shimokado, Kazuo Umezawa, Soichi Kojima

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Sangivamycin, an antibiotic with anti-tumor and anti-herpes virus activities by inhibiting both DNA/RNA synthesis and protein kinase C activity, was reported to suppress selectively DNA synthesis and growth of human umbilical vein endothelial cells and their tube formation in vitro. Here, to address the potential clinical use of sangivamycin in future, we investigated its anti-angiogenic effect in in vivo chicken chorioallantoic membrane (CAM) and mouse dorsal air sac (DAS) assays, and investigated underlying mechanism. Methods: The effect of sangivamycin on blood vessel formation in CAM was observed under the microscope after treating for two days. For DAS assays, chambers fulfilled with tumor cells were implanted beneath mouse dorsal skin. After the mice were administered with sangivamycin, tumor-induced angiogenesis was observed under the microscope. The effect of sangivamycin on ATP synthesis on the endothelial cell surface was assayed by measuring ATP production with bioluminescence assay. Results: Sangivamycin suppressed angiogenesis within CAM down to 94-71%, which was partially blocked by simultaneous addition of a 40-fold excess of adenosine. Sangivamycin also inhibited tumor-angiogenesis in the DAS assay by 61%, and suppressed ATP production on the endothelial cell surface by 75%. Conclusion: Sangivamycin inhibits the in vivo angiogenesis within CAM and tumor-induced angiogenesis within mouse dorsal skin, at least in part via inhibiting endothelial cell surface ATP metabolism in addition to inhibition of DNA/RNA synthesis and/or protein kinase C activity, suggesting a potential clinical use of sangivamycin as a novel anti-cancer reagent capable of targeting not only cancer cells but also endothelial cells.

Original languageEnglish
Pages (from-to)867-873
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume37
Issue number11
DOIs
Publication statusPublished - 2007 Nov

Fingerprint

sangivamycin
Adenosine Triphosphate
Chorioallantoic Membrane
Air Sacs
Neoplasms
Endothelial Cells
Protein Kinase C
DNA
RNA
Skin
Human Umbilical Vein Endothelial Cells

Keywords

  • ATP synthase
  • Sangivamycin
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Oncology

Cite this

Komi, Y., Ohno, O., Suzuki, Y., Shimamura, M., Shimokado, K., Umezawa, K., & Kojima, S. (2007). Inhibition of tumor angiogenesis by targeting Endothelial surface ATP synthase with sangivamycin. Japanese Journal of Clinical Oncology, 37(11), 867-873. https://doi.org/10.1093/jjco/hym115

Inhibition of tumor angiogenesis by targeting Endothelial surface ATP synthase with sangivamycin. / Komi, Yusuke; Ohno, Osamu; Suzuki, Yasuhiro; Shimamura, Mariko; Shimokado, Kentaro; Umezawa, Kazuo; Kojima, Soichi.

In: Japanese Journal of Clinical Oncology, Vol. 37, No. 11, 11.2007, p. 867-873.

Research output: Contribution to journalArticle

Komi, Y, Ohno, O, Suzuki, Y, Shimamura, M, Shimokado, K, Umezawa, K & Kojima, S 2007, 'Inhibition of tumor angiogenesis by targeting Endothelial surface ATP synthase with sangivamycin', Japanese Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-873. https://doi.org/10.1093/jjco/hym115
Komi, Yusuke ; Ohno, Osamu ; Suzuki, Yasuhiro ; Shimamura, Mariko ; Shimokado, Kentaro ; Umezawa, Kazuo ; Kojima, Soichi. / Inhibition of tumor angiogenesis by targeting Endothelial surface ATP synthase with sangivamycin. In: Japanese Journal of Clinical Oncology. 2007 ; Vol. 37, No. 11. pp. 867-873.
@article{efc345e8dbe041b188223ec6c086b9c5,
title = "Inhibition of tumor angiogenesis by targeting Endothelial surface ATP synthase with sangivamycin",
abstract = "Background: Sangivamycin, an antibiotic with anti-tumor and anti-herpes virus activities by inhibiting both DNA/RNA synthesis and protein kinase C activity, was reported to suppress selectively DNA synthesis and growth of human umbilical vein endothelial cells and their tube formation in vitro. Here, to address the potential clinical use of sangivamycin in future, we investigated its anti-angiogenic effect in in vivo chicken chorioallantoic membrane (CAM) and mouse dorsal air sac (DAS) assays, and investigated underlying mechanism. Methods: The effect of sangivamycin on blood vessel formation in CAM was observed under the microscope after treating for two days. For DAS assays, chambers fulfilled with tumor cells were implanted beneath mouse dorsal skin. After the mice were administered with sangivamycin, tumor-induced angiogenesis was observed under the microscope. The effect of sangivamycin on ATP synthesis on the endothelial cell surface was assayed by measuring ATP production with bioluminescence assay. Results: Sangivamycin suppressed angiogenesis within CAM down to 94-71{\%}, which was partially blocked by simultaneous addition of a 40-fold excess of adenosine. Sangivamycin also inhibited tumor-angiogenesis in the DAS assay by 61{\%}, and suppressed ATP production on the endothelial cell surface by 75{\%}. Conclusion: Sangivamycin inhibits the in vivo angiogenesis within CAM and tumor-induced angiogenesis within mouse dorsal skin, at least in part via inhibiting endothelial cell surface ATP metabolism in addition to inhibition of DNA/RNA synthesis and/or protein kinase C activity, suggesting a potential clinical use of sangivamycin as a novel anti-cancer reagent capable of targeting not only cancer cells but also endothelial cells.",
keywords = "ATP synthase, Sangivamycin, Tumor angiogenesis",
author = "Yusuke Komi and Osamu Ohno and Yasuhiro Suzuki and Mariko Shimamura and Kentaro Shimokado and Kazuo Umezawa and Soichi Kojima",
year = "2007",
month = "11",
doi = "10.1093/jjco/hym115",
language = "English",
volume = "37",
pages = "867--873",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Inhibition of tumor angiogenesis by targeting Endothelial surface ATP synthase with sangivamycin

AU - Komi, Yusuke

AU - Ohno, Osamu

AU - Suzuki, Yasuhiro

AU - Shimamura, Mariko

AU - Shimokado, Kentaro

AU - Umezawa, Kazuo

AU - Kojima, Soichi

PY - 2007/11

Y1 - 2007/11

N2 - Background: Sangivamycin, an antibiotic with anti-tumor and anti-herpes virus activities by inhibiting both DNA/RNA synthesis and protein kinase C activity, was reported to suppress selectively DNA synthesis and growth of human umbilical vein endothelial cells and their tube formation in vitro. Here, to address the potential clinical use of sangivamycin in future, we investigated its anti-angiogenic effect in in vivo chicken chorioallantoic membrane (CAM) and mouse dorsal air sac (DAS) assays, and investigated underlying mechanism. Methods: The effect of sangivamycin on blood vessel formation in CAM was observed under the microscope after treating for two days. For DAS assays, chambers fulfilled with tumor cells were implanted beneath mouse dorsal skin. After the mice were administered with sangivamycin, tumor-induced angiogenesis was observed under the microscope. The effect of sangivamycin on ATP synthesis on the endothelial cell surface was assayed by measuring ATP production with bioluminescence assay. Results: Sangivamycin suppressed angiogenesis within CAM down to 94-71%, which was partially blocked by simultaneous addition of a 40-fold excess of adenosine. Sangivamycin also inhibited tumor-angiogenesis in the DAS assay by 61%, and suppressed ATP production on the endothelial cell surface by 75%. Conclusion: Sangivamycin inhibits the in vivo angiogenesis within CAM and tumor-induced angiogenesis within mouse dorsal skin, at least in part via inhibiting endothelial cell surface ATP metabolism in addition to inhibition of DNA/RNA synthesis and/or protein kinase C activity, suggesting a potential clinical use of sangivamycin as a novel anti-cancer reagent capable of targeting not only cancer cells but also endothelial cells.

AB - Background: Sangivamycin, an antibiotic with anti-tumor and anti-herpes virus activities by inhibiting both DNA/RNA synthesis and protein kinase C activity, was reported to suppress selectively DNA synthesis and growth of human umbilical vein endothelial cells and their tube formation in vitro. Here, to address the potential clinical use of sangivamycin in future, we investigated its anti-angiogenic effect in in vivo chicken chorioallantoic membrane (CAM) and mouse dorsal air sac (DAS) assays, and investigated underlying mechanism. Methods: The effect of sangivamycin on blood vessel formation in CAM was observed under the microscope after treating for two days. For DAS assays, chambers fulfilled with tumor cells were implanted beneath mouse dorsal skin. After the mice were administered with sangivamycin, tumor-induced angiogenesis was observed under the microscope. The effect of sangivamycin on ATP synthesis on the endothelial cell surface was assayed by measuring ATP production with bioluminescence assay. Results: Sangivamycin suppressed angiogenesis within CAM down to 94-71%, which was partially blocked by simultaneous addition of a 40-fold excess of adenosine. Sangivamycin also inhibited tumor-angiogenesis in the DAS assay by 61%, and suppressed ATP production on the endothelial cell surface by 75%. Conclusion: Sangivamycin inhibits the in vivo angiogenesis within CAM and tumor-induced angiogenesis within mouse dorsal skin, at least in part via inhibiting endothelial cell surface ATP metabolism in addition to inhibition of DNA/RNA synthesis and/or protein kinase C activity, suggesting a potential clinical use of sangivamycin as a novel anti-cancer reagent capable of targeting not only cancer cells but also endothelial cells.

KW - ATP synthase

KW - Sangivamycin

KW - Tumor angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=37149023440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149023440&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym115

DO - 10.1093/jjco/hym115

M3 - Article

C2 - 17956898

AN - SCOPUS:37149023440

VL - 37

SP - 867

EP - 873

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -